ABCM
Abcam plc American Depositary SharesABCM
ABCM
Delisted
ABCM was delisted on the 5th of December, 2023.
About: Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.
Employees: 1,760
Financial journalist opinion
Neutral
GlobeNewsWire
9 months ago
Metabolism Assays Market Size Projected to Reach USD 3.1 Billion by 2034, Growing Steadily at 6.7% CAGR | Report by Transparency Market Research, Inc
Metabolism Assays Market Driven by Increase in Prevalence of Metabolic Disorders Metabolism Assays Market Driven by Increase in Prevalence of Metabolic Disorders
Positive
Reuters
1 year ago
Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
Neutral
PRNewsWire
1 year ago
Danaher Completes Acquisition of Abcam
WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023.
Neutral
Business Wire
1 year ago
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The.
Neutral
Business Wire
1 year ago
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam today announced that all Identified Clearances required in connection with the acquisition of the company by Danaher have been obtained.
Charts implemented using Lightweight Charts™